Evidence map›Paper›PMID 27173934›Full record

ArticleCell host & microbe2016

HIV-1 Vpu Mediates HLA-C Downregulation.

Richard Apps, Gregory Q Del Prete, Pramita Chatterjee, Abigail Lara, Zabrina L Brumme, Mark A Brockman, Stuart Neil, Suzanne Pickering, Douglas K Schneider, Alicja Piechocka-Trocha and 7 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell host & microbe, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
10.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 137 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. HIV-1 manipulates CD96 on CD4Science advances · 2025
    Article
  10. Article
  11. Article
  12. Review
  13. HIV controllers: hope for a functional cure.Frontiers in immunology · 2025
    Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. MHC Class I Ligands of Rhesus Macaque Killer Cell Ig-like Receptors.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
  20. Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 3 countries.

Richard AppsCancer and Inflammation Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Gregory Q Del PreteAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Pramita ChatterjeeCancer and Inflammation Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Abigail LaraAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Zabrina L BrummeFaculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V67 1Y6, Canada.
Mark A BrockmanFaculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC V67 1Y6, Canada.
Stuart NeilDepartment of Infectious Disease, King's College London School of Medicine, Guy's Hospital, London SE1 9RT, UK.
Suzanne PickeringDepartment of Infectious Disease, King's College London School of Medicine, Guy's Hospital, London SE1 9RT, UK.
Douglas K SchneiderAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Alicja Piechocka-TrochaRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139-3583, USA.
Bruce D WalkerRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139-3583, USA.
Rasmi ThomasHost Genetics Section, US Military HIV Research Program, Silver Spring, MD 20910, USA.
George M ShawDepartments of Medicine and Microbiology, University of Pennsylvania, Philadelphia, PA 19104-6076, USA.
Beatrice H HahnDepartments of Medicine and Microbiology, University of Pennsylvania, Philadelphia, PA 19104-6076, USA.
Brandon F KeeleAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA.
Mary CarringtonCancer and Inflammation Program, Leidos Biomedical Research, Frederick National Laboratory, Frederick, MD 21702, USA; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139-3583, USA. Electronic address: carringm@mail.nih.gov.
Leidos Biomedical Research Inc. (United States)Ragon Institute of MGH, MIT and Harvard · USUniversity of Pennsylvania · USAIDS Vancouver · CAGuy's Hospital · GBKing's College London · GBLeidos (United States) · USSimon Fraser University · CA

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI CRUMP, JOHN ANDREW · 2006 to 2011
$290.5M
Effects of genetic polymorphism in MHC, KIR, and related loci on human diseaseZIABC010791 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$18.2M
CCR NIH HHS HHSN261200800001CMedical Research Council G0801937NCI NIH HHS HHSN261200800001ENIAID NIH HHS U19 AI067854
6 · The paper itself

Abstract

Many pathogens evade cytotoxic T lymphocytes (CTLs) by downregulating HLA molecules on infected cells, but the loss of HLA can trigger NK cell-mediated lysis. HIV-1 is thought to subvert CTLs while preserving NK cell inhibition by Nef-mediated downregulation of HLA-A and -B but not HLA-C molecules. We find that HLA-C is downregulated by most primary HIV-1 clones, including transmitted founder viruses, in contrast to the laboratory-adapted NL4-3 virus. HLA-C reduction is mediated by viral Vpu and reduces the ability of HLA-C restricted CTLs to suppress viral replication in CD4+ cells in vitro. HLA-A/B are unaffected by Vpu, and primary HIV-1 clones vary in their ability to downregulate HLA-C, possibly in response to whether CTLs or NK cells dominate immune pressure through HLA-C. HIV-2 also suppresses HLA-C expression through distinct mechanisms, underscoring the immune pressure HLA-C exerts on HIV. This viral immune evasion casts new light on the roles of CTLs and NK cells in immune responses against HIV.

Indexed as

Base SequenceCD4-Positive T-LymphocytesCloning, MolecularCytotoxicity, ImmunologicDown-RegulationHeLa CellsHIV-1HIV InfectionsHLA-C AntigensHuman Immunodeficiency Virus ProteinsHumansImmune EvasionKiller Cells, NaturalMutationT-Lymphocytes, CytotoxicTransfectionHLA-C AntigensHuman Immunodeficiency Virus ProteinsViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1

Identifiers

PMID27173934
PMCPMC4904791
OpenAlexW2371536864

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.